



INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC2017/0006230				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		((kallikrein NEAR/10 plasmatic) NEAR/10 inhibitor) ((Pyrazole or imidazole) NEAR/10 carboxamide) before:publication:20151126 after:publication:19000101		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K31/415; A61K31/454; A61K31/4709; A61K31/497; A61K31/506; C07D231/14; C07D401/06; C07D401/10; C07D401/14; C07D403/10; C07D409/14; C07D413/14		
		CPC (Opcional): C07D231/14; C07D401/06; C07D401/10; C07D401/14; C07D403/10; C07D409/14; C07D413/14		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI (Obligatoria)	CO14026538	07/02/2014	---	A, Y
	CO15172558	27/07/2014	1	Y
	CO15296468	08/04/2016	1	P, Y
Patbase*	WO2008/016883	07/02/2008	1	Y
	WO2009/097141	06/08/2009	1	Y
	WO2016/083820	02/06/2016	1	P, Y
	WO2014/188211	27/11/2014	1	P, Y
Google Patents	US7115627	03/10/2006	---	A
	US6967208	22/11/2005	---	A
	US6399644	04/06/2002	---	A
Espacenet	WO2014/108679	17/07/2014	1, 2, 5 – 9 y 11	Y
	WO2013/111108	01/08/2013	1 – 4 y 11	Y
Orbit	WO2012/017020	09/02/2012	1	Y
	WO2011/100402	18/08/2011	---	A
	WO2012/142308	18/10/2012	---	A
	WO2013/022818	14/02/2013	---	A
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.			“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.	
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente **Se incluye entre otros, toda la referencia de la literatura no patente.	
---	--

Fecha del reporte de búsqueda:	11/07/2018
--------------------------------	------------

6 Casos asociados

Número de solicitud	Tipo de solicitud	Título/Denominación	Etiqueta	Fecha de radicación	Estado(s)	Examinador Principal	Titular
 14026538	Patente PCT	DERIVADOS DE BENCLAMINA COMO INHIBIDORES DE CALICREINA DEL PLASMA		07 feb 2014	Concedido	SIC	KALVISTA PHARMACEUTICALS LIMITED
 15172558	Patente PCT	COMPUESTOS DERIVADOS DE 4-AMINOMETILBENCLAMIDA		27 jul 2015	Abandonada	EDWIN YOVANI OVALLE DIAZ	KALVISTA PHARMACEUTICALS LIMITED
 15296458	Patente PCT	DERIVADOS 6,5- Y 6,6 HETEROCÍCLICOS COMO INHIBIDORES DE LA CALICREINA PLASMÁTICA Y COMPOSICIONES QUE CONTIENE LA MISMA		16 dic 2015	Concedido	EMILCE CANO URREGO	KALVISTA PHARMACEUTICALS LIMITED
 NC20160000424	NC Anualidad	Solicitado en Patente 14026538		28 jul 2016	Inscrita	MAURICIO EDUARDO BUITRAGO CAYCEDO	N/A
 NC2017/0006230	Patente PCT	INHIBIDORES DE CALICREINA PLASMÁTICA DERIVADOS DE PIRAZOL-4-CARBOXAMIDA		23 jun 2017	Bajo Examen de Fondo	LEONARDO FERNANDEZ RODRIGUEZ	KALVISTA PHARMACEUTICALS LIMITED
 NC2017/0006741	NC Modificación a las reivindicaciones	Solicitado en Patente NC2017/0006230		05 jul 2017	Inscrita	DAYRON ALEXANDER RAMÍREZ REYES	N/A
Seleccionar todo - Ninguno Mostrar / Ocultar columnas 							
Obtener lista de resultados							

fiveIPoffices - CCD

Number: [WO2016083820](#) [Search](#) examples: EP1612452, US2006000447A1, JP20090214944

[WO2015GB53615](#)

[Hide CCD viewer](#) [Double inspector](#) [Timeline](#)

CCD Viewer

[Citations only view](#) [Compact view](#) [Sort by country](#) [Filter](#)

#

CC

Cat.

Citation details

Claims

12

TW

Application N° TW20150139776 (TW104139776) - 27 November 2015

13

EP

Application N° EP20150804210 (EP1504210.1) - 26 November 2015

14

WO

Application N° WO2015GB53615 (WOG82015/053615) - 26 November 2015

International Search Report

X

WO2005049570 A1 (SHITIKHLINE BEECHAN CORP. [US], et al.) - 2 June 2005

* Formula (1); Intermediate 107; Example 46; claim - *

X

WO2007113289 A1 (GLAXO GROUP LTD [GB], et al.) - 11 October 2007

* Formula (1); Compounds C65, C36, C70; page 26; claim - *

Y

WO2013017920 A1 (NOVARTIS AG [CH], et al.) - 9 February 2012

* Formula (1); example - ; claim - *

D

WO2013111108 A1 (NOVARTIS AG [CH]) - 1 August 2013

* Formula (1); example - ; claim - *

Y

WO2014108679 A1 (KALVISTA PHARMACEUTICALS LTD [GB]) - 17 July 2014

* Formula (1); example - ; claim - *

D

WO2014188211 A1 (KALVISTA PHARMACEUTICALS LTD [GB]) - 27 November 2014

* Formula (1); example - ; claim - *

X

2-Thiophenecarboxamide

Publication data: Chemical catalogue: Akos Consulting and Solutions GmbH, 20081218 REGISTRY

* the whole document *

X

2-Thiophenecarboxamide, 4-[[3,5-dimethyl-1H-pyrazol-4-yl)methyl]-N-[[1-ethyl-2-pyrrolidinyl)methyl]-5-(4-morpholinyl)

Publication data: Chemical catalogue Akos Consulting and Solutions GmbH, 20090122 REGISTRY

* the whole document *

X

1H-Pyrazole-4-carboxamide, N-[[4-[[[2-amino-2-oxoethylamino]carbonyl]phenyl)methyl]-3-(4-methylphenyl)-5-[[4-methylphenyl)methyl]-

Publication data: Chemical catalogue: Ukrorgsynet Ltd, 20120803 REGISTRY

* the whole document *

X

1H-Pyrazole-4-carboxamide, N-[[4-[acetylaminophenyl)methyl]-3-(4-methylphenyl)-1-[[4-methylphenyl)methyl]

Author: N H

Publication data: Chemical catalogue: Ambinter, 20090802 REGISTRY

* the whole document *

Application WO2015GB53615

[Biblio](#) [Description](#) [Claims](#) [Original document](#)

Bibliographic data: WO 2016083820 (A1)

N-((het)arylmethyl)-heteroaryl-carboxamides as plasma kallikrein inhibitors,

Publication date: 2 June 2016

Inventor(s): DAVIE REBECCA LOUISE [GB]; EDWARDS HANNAH JOY [GB]; EVANS DAVID MICHAEL [GB]; HODGSON SIMON TEANBY [GB]

Applicant(s): KALVISTA PHARMACEUTICALS LTD [GB]

Classifications: **International:** C07D401/14; A61K31/415; A61K31/454; A61K31/4709; A61K31/497; A61K31/506; C07D231/14; C07D401/06; C07D401/10; C07D403/10; C07D409/14; C07D413/14
Cooperative: C07D401/14; C07D413/14; C07D231/14; C07D401/06; C07D401/10; C07D403/10; C07D409/14

Application number: WO2015GB53615 20151126

Priority number(s): GB20140021083 20141127

Simple families: 1 Total family members: 14

Google Patents

2 of 235

SEARCH TERMS

(kallikrein NEAR/10 plasmatic) NEAR/10 inhibitor

+ Synonym

(Pyrzole or imidazole) NEAR/10 carboxamide

+ Synonym

+ Synonym

SEARCH FIELDS

Date - Publication -

1900-01-01 - 2015-11-26

+ Inventor

+ Assignee

Patent Office - Language -

Status - Type -

About 235 results

[Download](#) [Result list](#)

Sort by: Relevance

Grouped by: None

Results / page: 100

n as plasma kallikrein inhibitors - ((6-amino-pyridin-3-yl) methyl) - ...

Grant JP580926782 • トリタシ・ブランドル・ノバルティス アーダー

Priority 2010-08-04 • Filing 2011-08-03 • Grant 2015-11-10 • Publication 2015-11-10

Formula I in free form or in salt form or in pharmaceutically acceptable salt form [in the formula, R¹ is hydrogen, oxygen and 5-membered monocyclic aromatic ring system containing 1 to 4 heteroatoms selected from sulfur, ...

5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

Application WO2013111108A1 • Stefanie Flohr • Novartis Ag

Priority 2012-01-27 • Filing 2013-01-25 • Publication 2013-08-01

The invention relates to a compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

Heterocyclic derivatives

Application WO2014188211A1 • Rebecca Louise DAVIE • Kalvista Pharmaceuticals Limited

Priority 2013-05-23 • Filing 2014-05-23 • Publication 2014-11-27

The present invention provides compounds of formula (I); compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such ...

Controllable ion-exchange membranes

Grant US646865781 • Zhizhong Hou • The Regents Of The University Of California

Priority 1998-12-04 • Filing 1998-12-04 • Grant 2002-10-22 • Publication 2002-10-22

Multilayered porous materials are formed by coating a porous substrate with a metal and adsorbing an organic layer comprising a recognition moiety onto the metal film. The recognition moiety interacts with an analyte of interest allowing for its detection, purification, etc. Suitable recognition ...

Support for high performance affinity chromatography and other uses

Grant US627248981 • Nicholas Abbott • The Regents Of The University Of California

Priority 1998-12-04 • Filing 1998-12-04 • Grant 2001-08-21 • Publication 2001-08-21

Multilayered particulate materials are formed by coating a particulate substrate with a metal and adsorbing an organic layer comprising a recognition moiety onto the metal film. The recognition moiety interacts with an analyte of interest allowing for its detection, purification, etc. Suitable ...

5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors

Abstract

The invention relates to a compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

Classifications

C07D471/04 Ortho-condensed systems

[View 12 more classifications](#)

WO2013111108A1

WO Application

[Find Prior Art](#) [Similar](#)

Other languages: French

Inventor: Stefanie Flohr, Christian Markt, Kengo Nemoto, Bernard Piret

Original Assignee: Novartis Ag

Priority date: 2012-01-27

Family: US (1) EP (1) WO (1)

Date	App/Pub Number	Status
2013-01-25	PCT/IB2013/050662	
2013-08-01	WO2013111108A1	Applicati

Info: Patent citations (3), Non-patent citations (12), Cited by (26), Legal events, Similar documents, Priority and Related Applications

External links: Espacenet, Global Dossier, PatentScope, Discuss

